BRAINSTORM CELL THERAPEUTICS INC. (BCLI): Nasdaq/NYSE listing notice — BCLI fails to regain Nasdaq MVLS compliance; delisting stayed pending Feb 25 hearing

BRAINSTORM CELL THERAPEUTICS INC.

Company previously failed to meet Nasdaq's minimum market value of listed securities requirement by Jan 14, 2025.
On Jan 21, 2025, submitted a hearing request to appeal the Staff's delisting determination.
Nasdaq confirmed hearing on Feb 25, 2025; delisting action is stayed pending final Panel decision.
Company will present plan to regain compliance and sustain long-term listing criteria.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq hearing update notice regarding market value.

Exchange: nasdaq
Notice: hearing update
Deficiency: market value

Exact text from the filing

January 21, 2025, the Company submitted a hearing request to the Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s determination. On the same day, the Company received a letter from Nasdaq notifying the Company t

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq hearing update notice regarding market value.

Exchange: nasdaq
Notice: hearing update
Deficiency: market value

Exact text from the filing

January 21, 2025, the Company submitted a hearing request to the Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s determination. On the same day, the Company received a letter from Nasdaq notifying the Company that, among other things, (i) the Panel hearing will be held on February 25, 2025, and (ii) the hearing request submitted by the Company has stayed the delisting action pending a final written decision by the Panel. At the hearing, the Company will demonstrate its ability to regain compliance with the deficiencies cited by the Staff, as well as its ability to sustain long-term c

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-25-004953

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.